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Background: Supplemental nocturnal oxygen is widely used for hypoxaemic respiratory failure in adults with CF.
Methods: In order to determine the factors that predict the development of progressive hypercapnia on oxygen (bfailure of oxygen therapyQ)
and the subsequent role of bi-level pressure support ventilation (BVS), we reviewed the outcomes of 39 adults with CF who were treated for
hypoxaemic respiratory failure between 1991 and 2002 using strict physiological criteria for the commencement of oxygen and the
subsequent commencement of BVS.
Results: Twenty of the 39 failed oxygen therapy, 13 of these within 12 months. Baseline PaCO2, rather than age, BMI or FEV1, predicted
failure of oxygen therapy within 12 months. A PaCO2N6.5 kPa (49 mm Hg) was significantly associated with failure within 12 months
( p=0.04). Twenty patients with mean PaCO2 7.9F1.3 kPa (59F10 mm Hg) and mean pH 7.38F0.05 had a significant reduction in their
mean PaCO2 after 1 month of BVS ( p=0.007).
Conclusions: Both oxygen and BVS can successfully stabilise patients to transplant. In patients commencing oxygen, baseline PaCO2 is
predictive of the development of progressive hypercapnia within 12 months. BVS can successfully attenuate the rise in PaCO2 in the short term.
D 2004 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
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The degree of respiratory impairment determines prog-
nosis in patients with cystic fibrosis (CF). Nocturnal
hypoxaemia often occurs prior to daytime abnormalities of
gas exchange. Supplemental oxygen reduces nocturnal
hypoxaemia, but in some patients at the expense of worsen-1569-1993/$ - see front matter D 2004 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2004.07.002
* Corresponding author. Tel.: +61 2 95157427; fax: +61 2 95158196.
E-mail addresses: cathd@mail.med.usyd.edu.au (C.J. Dobbin)8
mareem@mail.med.usyd.edu.au (M.A. Milross)8
ajp@mail.med.usyd.edu.au (A.J. Piper)8 ces@med.usyd.edu.au
(C. Sullivan)8 rrg@mail.med.usyd.edu.au (R.R. Grunstein)8
peterb@mail.med.usyd.edu.au (P.T.P. Bye).
1 Dr. Dobbin is supported by the National Health and Medical Research
Council of Australia.ing hypercapnia [1,2]. Long-term use of nocturnal oxygen in
patients with CF has not shown a survival advantage [3].
With the relentless progression of the underlying lung
disease both hypoxaemia and hypercapnia can worsen
despite oxygen therapy. Worsening hypercapnic respiratory
failure, as a marker of pulmonary deterioration, has been
strongly linked with reduced survival [4].
Non-invasive ventilation (NIV) has been proposed as a
means of temporarily ameliorating the above process. Some
studies have demonstrated its ability to unload respiratory
muscles and improve gas exchange, alveolar ventilation and
pulmonary mechanics over a single night [1,5,6]. It has been
used successfully to stabilise patients awaiting lung trans-
plantation, in some cases, for many months [7–9].
There are limited data on the time course of develop-
ment or progression of hypercapnia whilst on oxygen. At3 (2004) 237–242ed by Elsevier B.V. All rights reserved.
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physiological criteria for the initiation of nocturnal oxygen
therapy and the subsequent commencement of NIV in the
event of worsening hypercapnia on oxygen. For the last
11 years we have consistently applied these criteria to the
management of respiratory failure in our patients.
We hypothesised that the development of progressive
hypercapnia on nocturnal supplemental oxygen could be
predicted by patient characteristics at the time of
initiation of oxygen therapy. We examined the outcomes
of patients treated for respiratory failure in order to
determine the factors that predict worsening hypercapnia
whilst on oxygen, and the role of nocturnal NIV as a
rescue or maintenance therapy after supplemental oxygen
has failed. We hypothesised that NIV could at least
temporarily reverse hypercapnia with stabilisation of
respiratory failure in patients who had deteriorated despite
oxygen therapy.2. Materials and methods
2.1. Study subjects and design
The records of 39 adult patients from the RPAH Adult
Cystic Fibrosis Centre, who were treated with nocturnal
oxygen therapy from 1991 to 2002, including 20 who
subsequently met the criteria for initiation of NIV, were
reviewed. RPAH is the largest adult CF centre in NSW
currently servicing 175 adult patients [10]. The Central
Sydney Area Ethics Committee approved the study.
2.2. Methods
Spirometry was performed according to American
Thoracic Society guidelines [11]. Due to a lack of CF-
specific criteria, patients initiated nocturnal oxygen if,
when in a clinically stable state, they satisfied the Thoracic
Society of Australia and New Zealand criteria for
domiciliary oxygen [12] (Table 1), the official criteria for
oxygen prescription in Australia since the mid 1980s. At
baseline (prior to intervention), arterial blood gas tensions
(ABGs) were obtained from the patient while they were
seated and breathing room air. At varying time points after
initiation of the assigned intervention, as guided by clinical
condition, ABGs were repeated, either during the day or
evening on room air, or whilst using the assignedTable 1
Criteria for qualifying for supplemental nocturnal oxygen and non-invasive venti
Criteria for qualifying for supplemental oxygena Criteria
(a) PaO2b7.3 kPa (55 mm Hg) OR (a) Ris
(b) PaO2b7.9 kPa (59 mm Hg) with evidence of cor pulmonale OR (b) Ris
(c) Minimum nocturnal oxyhaemoglobin saturation b88% (c) Ab
a From Young et al. Med J Aust 1998; 168: 21-5; PaO2: arterial oxygen ten
TcCO2: transcutaneous carbon dioxide.intervention if taken in the early morning. bBaselineQ
was defined as the time immediately after which oxygen
therapy commenced. Oxygen was administered at home
via nasal prongs from a concentrator. Patients were
instructed to use the oxygen at night, whilst asleep. No
measures of compliance were made. Patients were moni-
tored for the development of hypercapnia with periodic
overnight oxyhaemoglobin saturation (SpO2) and trans-
cutaneous carbon dioxide (TcCO2) recordings in conjunc-
tion with evening and early morning ABGs. The
development of symptoms such as headaches and dis-
turbed sleep triggered clinical re-evaluation. Such symp-
toms at times occurred in the context of a pulmonary
exacerbation. Those patients using nocturnal oxygen who,
at any time, whether stable or during an exacerbation,
fulfilled the criteria for addition of NIV, as set out in Table
1, were switched to nocturnal NIV or had NIV added to
their oxygen in the form of bi-level pressure preset devices
(BVS) (VPAPII; ResMed, Sydney, Australia or BiPAP;
Respironics Inc, Pittsburgh, Pennsylvania).
All patients underwent inpatient acclimatisation to the
device, allowing daytime practice sessions. In the acute
setting a full-face mask was used in order to minimise air
leak. Patients were transferred to nasal masks as tolerated.
2.3. Treatment titration
Following acclimatisation, patients underwent overnight
oximetry and TcCO2 monitoring whilst on treatment with
either low-flow oxygen or BVS. Early morning ABGs were
obtained whilst the patient remained on treatment thereby
allowing determination of the rise in PaCO2 overnight
associated with that specific form of intervention.
Oxygen was commenced at 0.5 L/min and was titrated
up in order to maintain SpO2z90% whilst keeping the
rise in TcCO2 to a minimum. During titration of BVS the
inspiratory positive airway pressure (IPAP) was set
initially at 8–10 cm H20 and the expiratory positive
airway pressure (EPAP) at 4 cm H20. Pressures were
titrated to maintain SpO2z90% whilst minimising the rise
in TcCO2. The IPAP was increased according to patient
tolerance and the effect upon gas exchange. Air leak from
around the mask and mouth sometimes limited the extent
to which IPAP could be increased. If upper airway
obstruction or flow limitation was evident EPAP was
increased. In most patients a chinstrap was required to
minimise mouth leaks. Heated humidifiers were used tolation
for Qualifying for NIV
e in PaCO2z1.3 kPa (10 mm Hg) from baseline or pre oxygen ABGs OR
e in TcCO2z1.3 kPa (10 mm Hg) on overnight TcCO2 monitoring OR
solute PaCO2z8kPa (60 mm Hg)
sion; PaCO2: arterial carbon dioxide tension; ABGs: arterial blood gases;
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flow oxygen was added if, after optimal IPAP and EPAP
were obtained, SpO2 remained b90%.
2.4. Statistical analysis
Data were analysed using SAS Version 8 (SAS Institute,
Cary, NC). Characteristics of all patients treated with
oxygen and the twenty of these who at any time thereafter
were treated with BVS are expressed as meanFSD. Median
duration of therapy is reported. Five patients who underwent
lung transplantation within one year of commencing oxygen
were excluded from further analyses. The clinical endpoint
examined was bfailure of oxygen therapyQ within 12
months. bFailure of oxygen therapyQ occurred if patients
experienced a rise in PaCO2z1.3 kPa (10 mm Hg) from
baseline or pre oxygen ABGs or a rise in TcCO2z1.3 kPa
(10 mm Hg) on overnight TcCO2 monitoring or an absolute
PaCO2z8 kPa (60 mm Hg) or if they died whilst using
oxygen. Univariate analysis was used to compare patients
with this endpoint versus those without, with the use of an
unpaired Student’s t-test or the chi-squared test, as
appropriate. Multivariate logistic regression analysis was
then performed, with backward stepwise analysis, to
identify independent predictors of the endpoint. All com-
parisons of clinical variables with a p value b0.25 by
univariate analysis and the baseline FEV1% predicted were
entered into the model. We dichotomised PaCO2 at various
cut-points and used Fisher’s exact test to determine the
PaCO2 level when commencing oxygen, above which there
was a significant chance of bfailure of oxygen therapyQ
within 12 months. Statistical significance was assumed at
pb0.05. All probabilities were two tailed.3. Results
From 1991 to July 2002, 39 adults with CF commenced
nocturnal oxygen because of nocturnal or daytime hypo-
xaemia (Table 2). Of these, 20 at some time thereafterTable 2
Summary of patient outcomes based on status of gas exchange when treatment w
Gas exchange at
commencement
of treatment with O2
Requiring
BVS within
12 months
Requiring
BVS after
12 months
Died on O2
within
12 months
T
w
1
Daytime hypoxaemia,
hypercapnia
5 1 1 0
Daytime hypoxaemia,
eucapnia
2 2 0 1
Nocturnal desaturation,
hypercapnia
2 1 0 3
Nocturnal desaturation,
eucapnia
3 4 0 1
Total 12 8 1 5developed worsening hypercapnia, satisfying the criteria for
NIV and receiving treatment with nocturnal BVS.
3.1. Supplemental nocturnal oxygen
The characteristics of patients commencing nocturnal
oxygen are shown in Table 3. Most patients had severe
pulmonary impairment and a low body mass index (BMI).
Many were being considered for lung transplantation.
Eighteen patients (46%) fulfilled the criteria for supple-
mental oxygen on daytime resting room air ABGs.
Twenty-one (54%) had a minimum nocturnal SpO2b88%
(Table 2).
The duration of patients’ treatment with oxygen (range
1–116 months) was influenced by the time to transplantation
and the time to development of hypercapnia warranting
addition of BVS, both of which varied considerably. Some
patients were stable on oxygen alone for almost 3 years
before fulfilling the criteria for NIV.
3.2. Predictors of failure of oxygen therapy
Five patients received a lung transplant within 12 months
of commencing oxygen and were excluded from further
analysis. Of the remaining 34 patients, 13 failed oxygen
therapy within 12 months. One died and 12 developed
progressive hypercapnia requiring BVS. On univariate
analysis PaCO2 at the time of commencement of nocturnal
oxygen was significantly associated with failure of oxygen
therapy within 12 months (Table 4).
On multivariate analysis the only factor predictive of
failure of oxygen therapy within 12 months was baseline
PaCO2 (OR for every 0.13 kPa (1 mm Hg) rise in PaCO2,
1.22; 95% CI, 1.01–1.47; p=0.04). A baseline PaCO2N6.5
kPa (49 mm Hg) was significantly associated with failure of
oxygen therapy within 12 months ( p=0.04, Fisher’s exact
test).
Of the 21 patients who remained stable on oxygen at 12
months, eight later developed hypercapnia warranting
initiation of NIV, two died, nine remained stable on oxygenith oxygen commenced
ransplanted
ithin
2 months
Stable on O2 until
transplant (n=9) or
as of July 2002 (n=2);
treated for range
12–116 months
Died after treatment
with O2 for 30 and
26 months,
respectively
0 1 18
4 1
5 0 21
2 0
11 2 39
Table 4
Univariate analysis of clinical variables at baseline associated with failure
of oxygen therapy within twelve months
Variable Stable on
oxygen at
12 months,
n=21
Failure of
oxygen therapy
within 12 months,
n=13
p Value
Age, year 24F6 27F5 0.07
Males (%) 29 26 0.22
BMI, kg/m2 18F2 18F2 0.94
FEV1%
predicted
27F9 25F8 0.54
FVC%
predicted
41F15 38F15 0.59
PaCO2, kPa
(mm Hg)
5.7F0.5
(43F4)
6.3F0.8
(47F6)
0.04*
PaO2, kPa
(mm Hg)
7.9F1.1
(59F8)
7.7F0.9
(58F7)
0.63
DFEV1%
predicted
in
1 year
2F5 2F7 0.97
BMI: body mass index; FEV1% predicted: percent predicted forced
expiratory volume in 1 s; FVC% predicted: percent predicted forced vital
capacity in one second; PaO2: arterial oxygen tension; PaCO2: arterial
carbon dioxide tension; DFEV1% predicted in 1 year: change in percent
predicted forced expiratory volume in 1 s in 1 year.
* Significant pb0.05.
C.J. Dobbin et al. / Journal of Cystic Fibrosis 3 (2004) 237–242240until receiving lung transplants and two continue using
oxygen as of July 2002.
3.3. Effect of BVS after developing progressive hypercapnia
on oxygen therapy
Twenty patients commenced BVS after developing
progressive hypercapnia on oxygen and satisfying the
criteria for NIV in Table 1. In 14 patients (70%) daytime
room air ABGs revealed a rise in PaCO2 of at least 1.3 kPa
(10 mm Hg) from baseline and in six (30%) there was a rise
in TcCO2z1.3 kPa (10 mm Hg) on overnight TcCO2
recording whilst the patient was using supplemental oxygen.
Mean daytime room air PaCO2 rose from 6.1F0.8 kPa
(46F6 mm Hg) when commencing oxygen to 7.9F1.3 kPa
(59F10 mm Hg) when commencing BVS ( pb0.001, paired
t-test) after using oxygen for a median of 8 months. Mean
pH at the commencement of BVS was 7.38F0.05.
Concurrently these patients experienced a significant fall
in FEV1, from 25F8 to 21F8% predicted ( p=0.02, paired t-
test), and BMI, from 19F2 to 18F2 ( p=0.03, paired t-test).
After a mean stabilisation period of approximately one
month, use of BVS resulted in a fall in mean PaCO2 from
7.9F1.3 kPa (59F10 mm Hg) to 7.1F1.1 kPa (53F8 mm
Hg) ( p=0.007). IPAP required to achieve stabilisation
ranged from 10 to 18 cm H2O, and EPAP from 4 to 6
cmH2O. In some, BVS stabilised PaCO2 for months or years
and in others, progressive hypercapnia developed despite
BVS. Eleven patients underwent lung transplantation after
using NIV for a median of 7 months (range 2–27 months).
Eight died after using NIV for a median of 2 months (range
0.3–18 months). Five of these were on the transplant waiting
list when they died. Two were not listed for transplant
because of colonisation with Burkholderia cepacia. One
was not listed for transplant by choice. When she developedTable 3
Characteristics of patients when starting oxygen and when starting BVS
Variables Commenced
oxygen (n=39)
Commenced BVS for
progressive hypercapnia
(n=20)
Males, % 54 45
Age, year 26F6 27F5
BMI, kg/m2 18F2 18F2
Mean FEV1%pred 26F8 21F8
Mean FVC%pred 40F14 36F13
PaCO2, kPa (mm Hg) 6.4F0.7 (45F5) 7.9F1.3 (59F10)
PaO2, kPa
a (mm Hg) 7.7F0.9 (58F7) 8.1F2.8 (61F21)
Duration of therapy,
monthsb
12 (1–116) 6 (0.3–27)
Values are presented as meanFSD, apart from gender and duration of
therapy.
BMI: body mass index; FEV1%pred: percent predicted forced expiratory
volume in 1 s; FVC%pred: percent predicted forced vital capacity in 1 s;
PaO2: arterial oxygen tension; PaCO2: arterial carbon dioxide tension.
a Arterial blood gases for those commencing BVS are taken either on
room air or supplemental oxygen.
b Presented as median (range).an enlarging bullous cyst, although asymptomatic, a
decision was made to cease treatment with BVS.
One patient has been stable on BVS for 26 months and
continues using it as of July 2002. Whilst using BVS two
patients developed minor pneumothoraces, one of which did
not require an intercostal catheter. In neither case was
prolonged cessation of BVS required.4. Discussion
This is the first study to systematically evaluate the
outcome of respiratory failure in CF managed sequentially
with nocturnal oxygen then BVS. A major strength of this
study is that strict physiological criteria had to be met both
for the commencement of supplemental oxygen and the
subsequent use of BVS. Although oxygen therapy was able
to successfully maintain some patients to transplantation,
more than half the patients on supplemental oxygen for
hypoxaemia eventually required the addition of BVS
because they reached a pre-defined level of hypercapnia.
Bi-level ventilatory support successfully attenuated the rise
of PaCO2 and maintained at least half the patients to lung
transplantation.
The susceptibility of patients to the development of
hypercapnia whilst using supplemental oxygen varied
considerably. Some who were eucapnic when treatment
with oxygen commenced required BVS within 12 months,
whilst others who were hypercapnic when commencing
oxygen remained stable on oxygen for over a year (Table 2).
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the time of commencement of nocturnal oxygen, rather than
age, BMI or the degree of pulmonary impairment, was
predictive of the development of progressive hypercapnia,
as defined by our criteria, within 12 months. Patients with a
resting daytime PaCO2N6.5 kPa (49 mm Hg) when
commencing oxygen were at particular risk.
The degree of pulmonary impairment, age and BMI of
patients at baseline, were not predictive of failure of oxygen
therapy within 12 months. Although abnormalities of gas
exchange occur with deteriorating lung function, the extent
to which these two processes are coupled varies between
individuals. The development of progressive hypercapnia
was not associated with a more rapid rate of decline in FEV1
over a 1-year period. We caution against relying solely on
decline in FEV1 as a measure of deterioration and a trigger
for clinical re-assessment. Our results highlight the need for
close follow-up with ABGs for all patients commenced on
supplemental oxygen.
There are no disease-specific guidelines about the
appropriate time to initiate oxygen therapy in patients with
CF. Our specific physiological criteria for nocturnal oxygen
were derived from guidelines developed for patients with
COPD [12]. When CF patients qualified for oxygen based
on these COPD-derived criteria, most of them had severe
pulmonary impairment warranting consideration for trans-
plantation [4]. It could therefore be argued that oxygen
therapy was instituted too late in the disease process for
maximal benefit. A strategy for earlier intervention would
have been initiation of oxygen with evidence of nocturnal
desaturation alone, prior to marked levels of daytime arterial
hypoxaemia. Previous studies have identified daytime
characteristics predictive of nocturnal hypoxaemia [13–
15]. Prompt performance of overnight oximetry in patients
with these characteristics may facilitate earlier detection of
nocturnal hypoxaemia.
When should patients with CF commence BVS, if at
all? Hypercapnia, in particular a PaCO2N6.7 kPa (50 mm
Hg), is associated with a poor prognosis [4]. We took
advantage of what we perceived to be increased patient
tolerance of the bi-level pressure preset ventilatory devices
and initiated BVS, where possible, before the development
of acute respiratory acidosis. In most instances, our criteria
achieved this goal. The mean pH of patients commencing
BVS was 7.38. With adequate acclimatisation even
patients without marked hypercapnia when therapy com-
menced tolerated the pressure-preset devices on a long-
term basis. In previous audits using the less well-tolerated
volume preset ventilators, NIV was initiated in the acute
setting when most patients were acidotic [8,16,17]. In one
series the use of volume-preset ventilators did not correct
hypercapnia [17], most likely a reflection of the advanced
stage of the underlying lung disease when NIV was
applied. We have demonstrated the potential for BVS to be
applied to patients at an earlier stage than in the above
studies.Short-term or single night studies have demonstrated the
physiological benefits of BVS in patients with CF,
including reduced work of breathing [6], increased alveolar
ventilation [5] and facilitation of sputum expectoration
[18]. The prevention of the physiological, psychological
and metabolic effects of sustained hypercapnia and acidosis
[19–22] by the early application of BVS may also be
beneficial. However, caution is required. Without a control
group, our results cannot be used to advocate either early
application or long-term use of oxygen or BVS for CF
patients. In patients with Duchenne muscular dystrophy,
uncontrolled studies suggesting benefits from early appli-
cation of BVS were proved wrong when a controlled study
demonstrated increased mortality in those using BVS [23].
In the absence of a control group, our study gives no
information about the natural history of respiratory failure
progression in patients with CF. As treatment was allocated
sequentially, we do not know whether initial treatment of
respiratory failure with BVS, rather than oxygen alone,
would have been preferable in terms of slowing the
development of hypercapnia. Without prospective measures
of compliance it is not possible to be certain whether those
who developed rapid progression of hypercapnia on
oxygen were simply those who did or did not comply
with this therapy. Randomised controlled trials are required
to answer such questions.
We recognise other constraints, such as the small
numbers and retrospective nature of our data. Despite the
application of rigorous and consistent criteria for screening
of patients with blood gas analysis and overnight oximetry
over the entire time period, unavoidable patient factors
such as regularity of attendance at clinic for follow-up,
influenced the stage at which patients’ eligibility for
supplemental oxygen was detected. Also, no account was
taken of other potentially important determinants of
respiratory status including bacterial colonization, genotype
and diabetes.
Despite these limitations it does appear that the severity
of daytime hypercapnia at commencement of nocturnal
supplemental oxygen can be helpful in predicting the
likelihood of progression of hypercapnia within twelve
months. Although the utility of doing so is yet to be proven,
we have shown that bi-level pressure-preset ventilatory
support can be applied before the development of acute
respiratory acidosis and at lower levels of PaCO2 than
previously documented with volume preset devices. Use of
BVS at this early stage is effective at reducing mean PaCO2
within the first month. Thereafter, in some patients, BVS
can successfully stabilise gas exchange for 2 years or more
whilst they await transplantation. We suggest that use of
BVS be considered in any situation involving progressive
hypercapnia. The development of guidelines about the
timing of initiation of nocturnal oxygen or BVS for
respiratory failure in CF and information about a potential
survival advantage from early initiation of BVS will be
facilitated by further study in this area.
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